The U.S. peptide therapeutics (retail side) market size was estimated at USD 103.66 billion in 2024 and is expected to reach USD 336.12 billion by 2033, growing at a CAGR of 12.77% from 2025 to 2033. The increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, highlights the need for affordable and effective treatment options. In addition, the increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, underscores the need for affordable and effective treatment options. 

The increase in obesity and type 2 diabetes in the U.S. is driving demand for GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound). These medications enhance glycemic control and promote weight loss, making them effective for managing these chronic conditions. Patient awareness and physician preference are boosting their adoption. A 2024 JAMA Network Open study showed that spending on GLP-1 therapies grew from USD 13.7 billion in 2018 to over USD 71.7 billion in 2023, with retail pharmacies accounting for more than 70% of this increase. In 2024, tirzepatide's Zepbound reached USD 4.9 billion in sales, while Wegovy and Saxenda together generated USD 9.9 billion.

Download a free sample copy of the <U.S. Peptide Therapeutics (Retail Side)> market report to understand detailed coverage and inclusions in the final report

Innovation in peptide therapeutics is changing the patient experience by offering more convenient formats and broadening therapeutic options. FDA approvals for next-generation peptides such as dual agonists, once-weekly injectables, oral peptide pills, and generic/biosimilar versions are boosting the appeal of these drugs for both prescribers and patients. These advancements lessen the administration burden and enhance adherence, making them ideal for long-term outpatient use and retail dispensing. For example, according to the U.S. FDA in 2023, Eli Lilly’s tirzepatide (Zepbound) was approved for weight management after its success in treating diabetes, while Novo Nordisk’s Rybelsus (oral semaglutide) reached USD 1.7 billion in U.S. sales in 2022-demonstrating strong market acceptance of injection-free options.

The shift toward consumer-friendly healthcare delivery is fueling growth in the market. Traditional retail pharmacies (such as CVS, Walgreens, Walmart) and emerging telehealth platforms (such as Amazon Pharmacy, Ro, Hims & Hers) are increasingly offering peptide therapies either through prescription fulfillment or integrated consultation services. According to Eli Lilly in 2024, the company launched LillyDirect, a direct-to-consumer telehealth platform that allows patients to receive Zepbound and other peptide therapies at home. Novo Nordisk partnered with Ro and Hims & Hers to offer Wegovy at a discounted USD 499/month price for uninsured users, down from its retail list price of USD 1,349. Amazon Pharmacy, meanwhile, expanded GLP-1 fulfillment services across the country, with integrated pharmacist support and auto-refill capabilities.

Looking for more specific insights? Customize this report to suite your business needs

The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The X-axis represents the level of market concentration, ranging from low to high. The Y-axis represents various market characteristics, including industry competition, degree of innovation, level of mergers & acquisition activities, regulatory impact, product substitutes, and regional expansion.

Innovations include the evolution of drug formulations from traditional injectables to oral tablets and long-acting depot systems are improving convenience and accessibility for patients, making peptides more compatible with modern outpatient care. At the same time, the introduction of biosimilars and generics across key therapeutic categories is reducing price barriers and expanding treatment to broader population segments. For instance, Eli Lilly’s 2023 launch of Ngenla (somatrogon-ghla), a once-weekly growth hormone analog, provided an alternative to daily injections, improving pediatric adherence rates.

The market saw notable consolidations as larger companies are aimed to expand their reach and capabilities. For instance, in February 2025, Hims & Hers acquired a U.S.-based peptide production facility in California to bolster its domestic supply chain and improve the consistent delivery of personalized peptide-based medications. Melissa Baird, COO of Hims & Hers said:

Explore Grand View Horizon to see global and regional level statistics related to the <U.S. Peptide Therapeutics (Retail Side)> Market

 “The future of healthcare must be centered on the customer, which is why our operational structure is built to scale personalized care to more individuals at the highest standard of quality and safety, and with a focus on long-term consistency and availability.”

The FDA's classification of peptide therapies as biologics or drugs affects approval timelines, manufacturing requirements, and labelling, often resulting in higher development and compliance costs. This, in turn, influences retail pricing strategies and availability. For instance, GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound), which are peptide-based therapies for weight loss and diabetes, are subject to stringent regulatory oversight due to their biologic nature and high-demand profile.

The industry is experiencing significant expansion, driven by a combination of clinical innovation, increasing chronic disease prevalence, and favorable regulatory pathways. The FDA approval of Lutathera (lutetium Lu 177 dotatate) for gastroenteropancreatic neuroendocrine tumors and Zegalogue (dasiglucagon) for severe hypoglycemia reflect the growing acceptance and therapeutic potential of peptide drugs. Pharmaceutical companies are heavily investing in R&D, with firms like Amgen, Eli Lilly, and Ipsen expanding their peptide-based pipelines through both internal development and strategic acquisitions. In addition, the growing trend of personalized medicine and biologics has opened new niches for targeted peptide therapies.

Explore our Interactive market dashboard to get a bird's-eye view of the <U.S. Peptide Therapeutics (Retail Side)> Market

The U.S. peptide therapeutics market is moderately fragmented, comprising a mix of established retail pharmacy giants and emerging telehealth-enabled providers. Key players such as CVS Health, Walgreens Boots Alliance, Walmart Inc., The Kroger Co., and Costco Wholesale Corporation dominate the market with extensive pharmacy networks, specialty pharmacy services, and growing telehealth offerings to dispense peptide-based therapies. These companies are actively expanding their peptide therapy presence through partnerships with telehealth platforms, formulary additions of GLP-1 drugs, and affordable compounded peptide options to strengthen their competitive positioning and improve nationwide access.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

√    Focused market intelligence reports on specific geographies or high-growth segments.

√    Extended forecast timelines for long-term planning.

√    Competitor Benchmarking and Supply Chain Analysis

√    Inclusion of regulatory and policy assessments.

√    Inclusion of custom data models, KPIs, or applications unique to your business

√    Specific high-impact Data Decks and Tables to support effective decision making

And much more…